Æterna Zentaris

About Æterna Zentaris:

Æterna Zentaris Inc. is an oncology and endocrine therapy focused biopharmaceutical company with proven expertise in drug discovery, development and commercialization. The Company's broad, renewable product pipeline leverages five different therapeutic approaches, including LHRH antagonists and signal transduction inhibitors. The lead LHRH antagonist compound, cetrorelix, is currently marketed for in vitro fertilization under the brand name Cetrotide®, and has successfully completed a broad Phase II program in endometriosis and benign prostatic hyperplasia (BPH). The lead signal transduction inhibitor compound, perifosine, is an orally-active AKT inhibitor.

On the Market

Cetrotide® is the first LHRH antagonist treatment approved for in vitro fertilization

Impavido® is the first oral drug against visceral leishmaniasis, also known as black fever


The Pipeline:

Cetrotide®( cetrorelix) for Endometriosis

D-63153 Protate Cancer -BPH

Teverelix BPH- Prostate

Perifosine -- Multiple Cancers

Lobaplatin --Small cell lung cancer, breast, CML

Impavido --Parasitic skin disease

Neovastat --Non-small cell lung cancer

RC-3095 -- Multiple Cancers

Phase I Trials:

AN-152 Ovarian, endometrial and breast cancer

EP-1572 TBD

More on Æterna Zentaris:

Home Page

Key Statistics fo Æterna Zentaris

Basic Chart for Æterna Zentaris

Analyst Opinion

Analysts Estimates